24 stories found
Financial analysts have issued various insights and updated price targets for several major companies across different sectors, including Tesla, Qualcomm, and Biogen. These reports cover stock recommendations and market outlooks ahead of upcoming earnings seasons.
Amazon has announced its acquisition of satellite communications company Globalstar for over $11 billion, a move aimed at expanding its satellite internet service and intensifying its rivalry with Elon Musk's Starlink. Analysts are debating the deal's impact on Amazon's rocket launch capabilities.
An Innsbruck-based startup, ParaStruct, is developing innovative low-carbon building materials by utilizing mineral and biogenic waste products, as part of a regular startup feature in collaboration with i2b.
Biogen has indicated that its first-quarter net income per share will be negatively impacted by approximately $0.19.
Apellis Pharmaceuticals (APLS) stock has reached a two-year high, showing a 140% upside following its merger with Biogen.
Biogen is making a strategic move into the rare disease market with a $5.6 billion acquisition of Apellis Pharmaceuticals, aiming to expand its portfolio in this specialized area.
Biogen and Alteogen have finalized a new licensing deal specifically for injectable products, further expanding their pharmaceutical portfolios.
An analysis suggests that Biogen (BIIB) is an attractive holding for long-term investors.
Zacks.com featured highlights include Biogen, TE Connectivity, and ZTO Express (Cayman), indicating notable performance or analysis for these companies.
Piper Sandler has raised Biogen's stock rating to Overweight, citing the company's acquisition of Apellis as the reason for the upgrade. This reflects a positive financial outlook for Biogen.
Morgan Stanley has increased its price target for Vertex Pharmaceuticals to $612 from $596, indicating a positive outlook for the company's stock.
Following a significant $5.6 billion buyout, Biogen is now redirecting its strategic focus towards early-stage assets in its portfolio.
Apellis Pharma's stock has seen a significant surge following a deal with Biogen, leading investors to question if it's too late to capitalize on the APLS stock rally.
Biogen has secured approval from the FDA for a higher dosage of its drug designed to treat a genetic disorder.
An analysis evaluates whether Biogen's stock (BIIB) is currently outperforming the broader healthcare sector, examining its market performance.
Three doctors and a science journalist are facing a legal dispute after receiving a claim from the Endobiogenics Institute regarding a social media post about endobiogenics.
Zacks.com has released its featured highlights, recommending investments in Biogen, TE Connectivity, and ZTO Express (Cayman).
Biotech firm Biogen is projected to maintain growth despite anticipated lower royalties for its drug Ocrevus after patent expiration, supported by its development of other medicines, according to Piper Sandler.
Biogen's stock saw a sharp drop on Monday, leading to investor concerns and analysis of the reasons behind the decline.
Biogen has announced the acquisition of Apellis for $5.6 billion, a move aimed at strengthening its pipeline for rare disease treatments.
Biogen has agreed to acquire Apellis Pharmaceuticals for approximately $5.6 billion, a deal that will expand Biogen's portfolio of rare-disease and kidney disease medicines by adding C3 therapies. The company is now detailing the deal, projecting mid-to-high-teens growth and EPS accretion by 2027.
Biogen has received approval from the U.S. Food and Drug Administration for its high-dose Spinraza regimen, a treatment for spinal muscular atrophy.
The energy sector is focusing on biogenic CO2 as a potential new fuel source to help decarbonize air transportation, exploring its capabilities as a byproduct.
Wall Street analysts are providing target price analyses for Biogen stock.